OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of “Moderate Buy” by Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $17.5714.

A number of research analysts recently issued reports on OPRX shares. Zacks Research upgraded shares of OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, March 13th. Roth Mkm cut their target price on shares of OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Lake Street Capital reduced their price target on shares of OptimizeRx from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Finally, Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 6th.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds have recently modified their holdings of the business. CenterBook Partners LP acquired a new position in shares of OptimizeRx in the 3rd quarter valued at approximately $6,331,000. Hillsdale Investment Management Inc. raised its holdings in OptimizeRx by 10.9% during the 4th quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock worth $249,000 after buying an additional 2,000 shares during the period. State of Alaska Department of Revenue acquired a new stake in OptimizeRx during the 4th quarter worth approximately $62,000. Harbor Capital Advisors Inc. lifted its stake in OptimizeRx by 12.2% in the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after buying an additional 2,708 shares in the last quarter. Finally, Granahan Investment Management LLC acquired a new position in shares of OptimizeRx in the third quarter valued at approximately $1,456,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Trading Down 5.2%

NASDAQ:OPRX opened at $6.60 on Friday. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a 1-year low of $5.54 and a 1-year high of $22.25. The firm has a market capitalization of $123.82 million, a price-to-earnings ratio of 25.39 and a beta of 1.20. The business’s 50-day moving average price is $8.62 and its two-hundred day moving average price is $13.57.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. On average, equities analysts expect that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx declared that its board has initiated a share repurchase plan on Thursday, March 5th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.